Skip to content

Publications

Recent publications: https://www.ncbi.nlm.nih.gov/myncbi/jung%20wook.park.2/bibliography/public/
  1. Varuzhanyana G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzade S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. PNAS 2024 Nov
  2. Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, Sheu KM, Cheng D, Ta L, Varuzhanyan G, Huang A, Xu R, Zeng Y, Borujerdpur A, Bayley NA, Noguchi M, Mao Z, Morrissey C, Corey E, Nelson PS, Zhao Y, Huang J, Park JW, Witte ON, Graeber TG. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023 Dec 11;41(12):2066-2082.e9. doi: 10.1016/j.ccell.2023.10.009. Epub 2023 Nov 22. PubMed PMID: 37995683; PubMed Central PMCID: PMC10878415.
  3. VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. Targeting RET Kinase in Neuroendocrine Prostate Cancer.Mol Cancer Res. 2020 Aug;18(8):1176-1188. doi: 10.1158/1541-7786.MCR-19-1245. Epub 2020 May 27. PubMed PMID: 32461304; PubMed Central PMCID: PMC7415621.
  4. Wang L, Smith BA, Balanis NG, Tsai BL, Nguyen K, Cheng MW, Obusan MB, Esedebe FN, Patel SJ, Zhang H, Clark PM, Sisk AE, Said JW, Huang J, Graeber TG, Witte ON, Chin AI, Park JW. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):563-572. doi: 10.1073/pnas.1915770117. Epub 2019 Dec 23. PubMed PMID: 31871155; PubMed Central PMCID: PMC6955337.
  5. Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci Transl Med. 2019 Dec 4;11(521). doi: 10.1126/scitranslmed.aax0428. PubMed PMID: 31801883; PubMed Central PMCID: PMC7238624.
  6. Balanis NG, Sheu KM, Esedebe FN, Patel SJ, Smith BA, Park JW, Alhani S, Gomperts BN, Huang J, Witte ON, Graeber TG. Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. Cancer Cell. 2019 Jul 8;36(1):17-34.e7. doi: 10.1016/j.ccell.2019.06.005. PubMed PMID: 31287989; PubMed Central PMCID: PMC6703903.
  7. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, Smith BA, Cheng C, Tsai BL, Cheng D, Huang J, Kurdistani SK, Graeber TG, Witte ON. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018 Oct 5;362(6410):91-95. doi: 10.1126/science.aat5749. PubMed PMID: 30287662; PubMed Central PMCID: PMC6414229.
  8. Smith BA, Balanis NG, Nanjundiah A, Sheu KM, Tsai BL, Zhang Q, Park JW, Thompson M, Huang J, Witte ON, Graeber TG. A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. Cell Rep. 2018 Sep 18;24(12):3353-3366.e5. doi: 10.1016/j.celrep.2018.08.062. PubMed PMID: 30232014; PubMed Central PMCID: PMC6382070.
  9. Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. doi: 10.1073/pnas.1802354115. Epub 2018 Apr 23. PubMed PMID: 29686080; PubMed Central PMCID: PMC5949005.
  10. Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017 Sep;30(9):1262-1272. doi: 10.1038/modpathol.2017.44. Epub 2017 Jun 16. PubMed PMID: 28621319; PubMed Central PMCID: PMC6330177.
  11. Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, Zhang L, Huang K, Stoyanova T, Park JW, Shkhyan RO, Nowroozizadeh B, Rettig MB, Sawyers CL, Elashoff D, Horvath S, Huang J, Witte ON, Goldstein AS. Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep. 2016 Dec 6;17(10):2596-2606. doi: 10.1016/j.celrep.2016.11.010. PubMed PMID: 27926864; PubMed Central PMCID: PMC5367888.
  12. Park JW, Lee JK, Phillips JW, Huang P, Cheng D, Huang J, Witte ON. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7. doi: 10.1073/pnas.1603645113. Epub 2016 Apr 4. PubMed PMID: 27044116; PubMed Central PMCID: PMC4843433.
  13. Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31. PubMed PMID: 27050099; PubMed Central PMCID: PMC4829466.

 

Sites@Duke Express is powered by WordPress. Read the Sites@Duke Express policies and FAQs, or request help.